79,900 Shares in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Acquired by Natixis

Natixis purchased a new stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 79,900 shares of the company's stock, valued at approximately $645,000. Natixis owned about 0.11% of ORIC Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of the business. KLP Kapitalforvaltning AS purchased a new position in shares of ORIC Pharmaceuticals during the 4th quarter valued at approximately $50,000. PNC Financial Services Group Inc. raised its holdings in ORIC Pharmaceuticals by 22.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company's stock valued at $109,000 after acquiring an additional 2,520 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in ORIC Pharmaceuticals by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,963 shares of the company's stock valued at $121,000 after acquiring an additional 1,395 shares during the last quarter. ExodusPoint Capital Management LP acquired a new position in ORIC Pharmaceuticals during the 4th quarter worth $189,000. Finally, Invesco Ltd. increased its position in shares of ORIC Pharmaceuticals by 8.5% in the 4th quarter. Invesco Ltd. now owns 23,958 shares of the company's stock worth $193,000 after purchasing an additional 1,876 shares during the last quarter. Institutional investors and hedge funds own 95.05% of the company's stock.

ORIC Pharmaceuticals Price Performance

NASDAQ:ORIC traded up $0.37 during midday trading on Tuesday, reaching $5.46. 108,409 shares of the company traded hands, compared to its average volume of 632,728. The firm has a market capitalization of $387.45 million, a price-to-earnings ratio of -2.99 and a beta of 1.38. The company has a fifty day moving average price of $6.33 and a 200 day moving average price of $8.30. ORIC Pharmaceuticals, Inc. has a twelve month low of $3.90 and a twelve month high of $14.67.

ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last announced its quarterly earnings results on Tuesday, February 18th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.01. On average, equities research analysts forecast that ORIC Pharmaceuticals, Inc. will post -2.17 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on ORIC shares. HC Wainwright reaffirmed a "buy" rating and set a $21.00 price target on shares of ORIC Pharmaceuticals in a research report on Friday, February 21st. JPMorgan Chase & Co. lifted their target price on ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Cantor Fitzgerald reiterated an "overweight" rating on shares of ORIC Pharmaceuticals in a report on Tuesday, January 14th. Guggenheim restated a "buy" rating on shares of ORIC Pharmaceuticals in a research note on Wednesday, February 26th. Finally, Wedbush reiterated an "outperform" rating and set a $20.00 target price on shares of ORIC Pharmaceuticals in a research note on Thursday, March 20th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, ORIC Pharmaceuticals currently has a consensus rating of "Buy" and an average price target of $18.86.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.